Terms ending in 2030
Every in-force patent on Merck Sharp and Dohme LLC's record whose computed term ends in 2030, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,318,760 | Substituted Aryl and Heteroaryl Derivatives, Compositions Containing Such Compounds and Methods of Use In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | |
| US 8,357,709 | 2,4-Disubstituted Pyrrolidine Orexin Receptor Antagonists In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | |
| US 8,415,346 | Inhibitors of Janus Kinases In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | |
| US 9,359,339 | Glucagon Receptor Antagonist Compounds, Compositions Containing Such Compounds and Methods of Use In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | |
| US 8,591,878 | Therapeutic Compounds In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | |
| US 8,426,598 | N-Heterocyclic M1 Receptor Positive Allosteric Modulators In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | |
| US 9,278,965 | Bridged and Fused Antidiabetic Compounds In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | |
| US 8,691,205 | Mono- and Di-Peg IL-10 Production; and Uses In force · High confidence | Merck Sharp & Dohme Corp. | In force | High confidence | |
| US 7,973,040 | Macrocyclic Quinoxaline Compounds as HCV NS3 Protease Inhibitors In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | |
| US 8,507,477 | 3- and 6-Quinolines with N-Attached Heterocyclic CGRP Receptor Antagonists In force · High confidence | Merck Sharp & Dohme LLC | In force | High confidence | |
| 140 more term ends in 2030 · Pro | |||||
10 of 150 patents shown. Soonest term end first, then patent number.
Pro members see all 150.
138 of these are in force and held by Merck Sharp and Dohme LLC.
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.